Matthew Scaramozza Selected Research

Multiple Sclerosis

1/2021	Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
3/2014	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Scaramozza Research Topics

Disease

2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Multiple Sclerosis 01/2021 - 03/2014
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 01/2018
1	Neoplasms (Cancer) 01/2013
1	Relapsing-Remitting Multiple Sclerosis 01/2013

Drug/Important Bio-Agent (IBA)

2	PF-06700841IBA 01/2020 - 01/2018
2	Cladribine FDA LinkGeneric 03/2014 - 01/2013
1	BIIB091IBA 01/2021
1	Janus Kinase 1IBA 01/2020
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020
1	CytokinesIBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2020
1	TabletsIBA 01/2013

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2021